^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ARG1 overexpression

    i
    Other names: ARG1, Arginase 1, Arginase-1, Liver-Type Arginase, Arginase, Liver, Type I Arginase
    Entrez ID:
    383
    almost2years
    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    ARG1 overexpression • CD163 expression
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    almost2years
    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2028 --> May 2028 | Trial primary completion date: Feb 2028 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    ARG1 overexpression • CD163 expression
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    2years
    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Dec 2023 --> Feb 2024
    Trial initiation date
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    ARG1 overexpression • CD163 expression
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    2years
    Radiation Therapy and Myeloid-derived Suppressor Cells: Breaking Down Their Cancerous Partnership. (PubMed, Int J Radiat Oncol Biol Phys)
    This review will discuss how radiation promotes tumor resistance through activation of immunosuppressive MDSC in the TME. It will explain current research targeting MDSC, which could serve as a promising clinical treatment strategy in the future.
    Licensing / partnership • Review • Journal • IO biomarker
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • STING (stimulator of interferon response cGAMP interactor 1) • ARG1 (Arginase 1) • CCR2 (C-C Motif Chemokine Receptor 2)
    |
    ARG1 overexpression
    over2years
    DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. (PubMed, Oncogene)
    Furthermore, high stromal arginase-1 expression correlated with poor survival in ovarian cancer patients. These findings highlight how DDR2 regulates collagen production by CAFs in the tumor microenvironment by controlling the transcription of arginase-1, and CAFs are a major source of arginase activity and L-arginine metabolites in ovarian cancer models.
    Journal
    |
    DDR2 (Discoidin domain receptor 2) • ARG1 (Arginase 1) • SNAI1 (Snail Family Transcriptional Repressor 1)
    |
    ARG1 overexpression
    over2years
    Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    ARG1 overexpression • CD163 expression
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    3years
    Arginase 1 is a key driver of immune suppression in pancreatic cancer. (PubMed, Elife)
    Treatment of established tumors with the arginase inhibitor CB-1158 exhibited further increased CD8 T cell infiltration, beyond that seen with the macrophage-specific knockout, and sensitized the tumors to anti-PD1 immune checkpoint blockade. Our data demonstrate that Arg1 drives immune suppression in pancreatic cancer by depleting Arginine and inhibiting T cell activation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ARG2 (Arginase 2)
    |
    ARG1 overexpression
    |
    numidargistat (INCB001158)
    3years
    Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells. (PubMed, Cancer Metab)
    Activation of ARG1 is related to the migration ability and metastatic colonization of colon cancer cells, and blockade of this process may be a novel strategy for controlling cancer malignancy.
    Journal • Metastases
    |
    ARG1 (Arginase 1)
    |
    ARG1 overexpression